<DOC>
	<DOCNO>NCT00002667</DOCNO>
	<brief_summary>RATIONALE : Using new method examine sputum sample presence cancer cell may detect lung cancer earlier . PURPOSE : Screening trial study effectiveness new method examine sputum sample detect second primary lung cancer patient resect stage I non-small cell lung cancer .</brief_summary>
	<brief_title>Early Detection Second Lung Cancer Patients With Stage I Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate whether immunostaining induced sputum specimens improve sensitivity specificity routine morphologic sputum surveillance detect second primary lung cancer patient previously resect nonsmall cell lung cancer . II . Evaluate patient risk develop second primary lung cancer immunostaining specimen patient morphologic atypia routine Papanicolaou cytology . III . Make available archive sputum sample bronchial washing analysis new antibody technique . IV . Evaluate whether analysis elevation relevant growth factor bronchial lavage fluid patient positive immunostaining morphologic atypia increase accuracy early detection . V. Evaluate whether quantitation shed antigen sputum increase accuracy early detection . VI . Evaluate whether extent airway obstruction , measure forced expiratory volume , predict increase risk develop lung cancer . OUTLINE : Screening Second Primary Lung Cancer . Annual sputum induction Papanicolaou cytology immunostaining ( use monoclonal antibody 624H12 703D4 ) , optional pulmonary function test fiberoptic bronchoscopy bronchial washing . PROJECTED ACCRUAL : 1,100 patient enter 3 year . The sample size adjust base rate positive staining first 100 patient . Patients follow uncertified center analyze separately .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Stage I ( T12 N0 ) nonsmall cell lung cancer curatively resect regular followup least 6 week Material available histologic review At least 1 mediastinal node station sample least 2 year since surgery Any follow histology eligible : Squamous cell carcinoma Large cell carcinoma Adenocarcinoma ( include bronchoalveolar ) No small cell anaplastic component No recurrent disease second primary No synchronous lung cancer different histology Concurrent registration intergroup protocol I910001 allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Cardiovascular : No history severe hypertension , i.e . : Systolic 200 mm Hg Diastolic 120 mm Hg No MI within 6 week Pulmonary : Available annual sputum induction clinical evaluation Clinically able undergo pulmonary function test ( PFTs ) bronchoscopy Refusal PFTs bronchoscopy effect eligibility PFTs waive FEV1/FVC &lt; 65 % prior test No acute respiratory infection Other : No prior uncontrolled malignancy except nonmelanomatous skin cancer Exceptions malignancy control 5 year discretionary PRIOR CONCURRENT THERAPY : Complete surgical resection require primary therapy At least 6 week since resection , adjuvant chemotherapy radiotherapy , thoracoabdominal surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
</DOC>